Direct Phase II SBIR Grants to Support Biomedical Technology Development
The summary for the Direct Phase II SBIR Grants to Support Biomedical Technology Development grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Direct Phase II SBIR Grants to Support Biomedical Technology Development: The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to-Phase II SBIR grant mechanism. Applications are invited from eligible United States small business concerns (SBCs) that have demonstrated the scientific and technical merit and feasibility of the prototype stage of developing a biomedical technology that has commercial potential, R&D that is characteristic of Phase-I (R43) SBIR projects. The Direct-to-Phase II grant mechanism is intended to facilitate SBIR-type R&D, to expand R&D opportunities for applicant small business concerns (SBCs), and to enhance the pace of technology development and commercialization.
Federal Grant Title: | Direct Phase II SBIR Grants to Support Biomedical Technology Development |
Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
Grant Categories: | Education Health Income Security and Social Services |
Type of Opportunity: | Discretionary |
Funding Opportunity Number: | PAR-14-088 |
Type of Funding: | Grant |
CFDA Numbers: | 93.121, 93.172, 93.173, 93.233, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.351, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.838, 93.839, 93.846, 93.853, 93.855, 93.856, 93.859, 93.865, 93.866, 93.867 |
CFDA Descriptions: | Information not provided |
Current Application Deadline: | January 7th, 2017 |
Original Application Deadline: | January 7th, 2017 |
Posted Date: | February 5th, 2014 |
Creation Date: | February 5th, 2014 |
Archive Date: | February 7th, 2017 |
Total Program Funding: | |
Maximum Federal Grant Award: | |
Minimum Federal Grant Award: | |
Expected Number of Awards: | |
Cost Sharing or Matching: | No |
Last Updated: | February 19th, 2014 |
- Applicants Eligible for this Grant
- Small businesses
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
- Link to Full Grant Announcement
- http://grants.nih.gov/grants/guide/pa-files/PAR-14-088.html
- Grant Announcement Contact
- NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster - Similar Government Grants
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • NIDCR Mentoring Network to Promote a Diverse Dental, Oral and Craniofacial Research Workfo...
- • Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparit...
- • Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Cl...
- • Building Interdisciplinary Research Careers in Women's Health (BIRCWH) (K12 Clinical Trial...
- • Epidemiological and Behavioral Research in Oral Health
- • Metagenomic Analyses of the Oral Microbiome
- • Phase Iii Clinical Trials in Oral Infectious Diseases
- More Grants from the National Institutes of Health
- • HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
- • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
- • Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
- • AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
- • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)